Clinical observation of evolocumab combined with atorvastatin in the treatment of borderline coronary artery disease

SU Ruiya; WANG Lichuang; ZHANG Ou; ZENG Xianfeng; WEN Xian

doi:10.6039/j.issn.1001-0408.2026.10.14

您当前的位置：

首页 >

文章列表页 >

Clinical observation of evolocumab combined with atorvastatin in the treatment of borderline coronary artery disease

更新时间：2026-05-26

- Clinical observation of evolocumab combined with atorvastatin in the treatment of borderline coronary artery disease
- ZHONGGUO YAOFANG Vol. 37, Issue 10, Pages: 1318-1322(2026)
- 作者机构：
  
  1.南阳医学高等专科学校第一附属医院冠心病监护病房，河南南阳　473000
  2.南阳医学高等专科学校临床医学系，河南南阳　473000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.10.14
  CLC： R969.4;R541.4
- Received：12 January 2026，
  
  Revised：2026-04-17，
  
  Accepted：19 April 2026，
  
  Published：30 May 2026
- 稿件说明：
移动端阅览
苏蕊雅,王力闯,张鸥,等.依洛尤单抗联合阿托伐他汀治疗冠心病临界病变的临床观察 ^Δ[J].中国药房,2026,37(10):1318-1322. DOI: 10.6039/j.issn.1001-0408.2026.10.14.

SU Ruiya,WANG Lichuang,ZHANG Ou,et al.Clinical observation of evolocumab combined with atorvastatin in the treatment of borderline coronary artery disease[J].ZHONGGUO YAOFANG,2026,37(10):1318-1322.
苏蕊雅,王力闯,张鸥,等.依洛尤单抗联合阿托伐他汀治疗冠心病临界病变的临床观察 ^Δ[J].中国药房,2026,37(10):1318-1322. DOI: 10.6039/j.issn.1001-0408.2026.10.14. DOI：

SU Ruiya,WANG Lichuang,ZHANG Ou,et al.Clinical observation of evolocumab combined with atorvastatin in the treatment of borderline coronary artery disease[J].ZHONGGUO YAOFANG,2026,37(10):1318-1322. DOI： 10.6039/j.issn.1001-0408.2026.10.14.

摘要

目的

观察依洛尤单抗联合阿托伐他汀治疗冠心病（CHD）临界病变患者的临床疗效。

方法

采用回顾性队列研究，收集南阳医学高等专科学校第一附属医院2021年8月至2024年6月确诊为CHD临界病变的住院患者342例，根据治疗方案将患者分为对照组（采用阿托伐他汀治疗，190例）和试验组（采用依洛尤单抗联合阿托伐他汀治疗，152例）。经倾向评分匹配后，比较两组患者治疗前和治疗1年后的血脂指标、高敏C反应蛋白（hs-CRP）、冠脉血管内超声指标数据及心血管不良事件发生率。

结果

最终共纳入295例（对照组158例、试验组137例）患者进行分析。治疗1年后，相比同期对照组，试验组患者的总胆固醇、甘油三酯、低密度脂蛋白胆固醇及hs-CRP水平均显著降低（

＜0.05），高密度脂蛋白胆固醇水平显著升高（

＜0.05），血管腔直径、血管腔面积、最小管腔面积均显著增大（

＜0.05），斑块面积及斑块负荷均显著减小（

＜0.05）。试验组患者总不良事件的发生率显著低于对照组（

＜0.05）。

结论

依洛尤单抗联合阿托伐他汀能显著改善CHD临界病变患者的冠脉血管狭窄、斑块负荷，并降低心血管不良事件的发生率。

Abstract

OBJECTIVE

To observe the clinical efficacy of evolocumab combined with atorvastatin in the treatment of patients with borderline coronary heart disease （CHD）.

METHODS

In this retrospective cohort study， 342 hospitalized patients diagnosed with borderline CHD were enrolled in the First Affiliated Hospital of Nanyang Medical College from August 2021 to June 2024， and divided into control group （treated with atorvastatin， 190 cases） and trial group （treated with evolocumab combined with atorvastatin， 152 cases） according to therapeutic regimen. Blood lipid indexes， high-sensitivity C-reactive protein （hs-CRP） and intravascular ultrasound of the coronary artery at baseline and after 1 year of treatment， and incidence of cardiovascular adverse events were compared after propensity score matching.

RESULTS

A total of 295 patients （158 in control group and 137 in trial group） were finally included in the analysis. One year after the treatment， compared with control group， total cholesterol， triglycerides， low-density lipoprotein cholesterol and hs-CRP levels were decreased significantly in trial group （

＜0.05）， whereas high-density lipoprotein cholesterol level was increased significantly （

＜0.05）. The lumen diameter， lumen area， and the minimum lumen area were significantly increased （

＜0.05）， while plaque area and plaque burden were significantly decreased （

＜0.05）. Overall incidence of adverse events in trial group was significantly lower than that in control group （

＜0.05）.

CONCLUSIONS

Evolocumab combined with atorvastatin can significantly improve coronary luminal narrowing and reduce plaque burden， as well as reduce the incidence of cardiovascular adverse events in patients with borderline CHD.

关键词

Keywords

references

中华医学会心血管病学分会，中华心血管病杂志编辑委员会 . 急性ST段抬高型心肌梗死诊断和治疗指南 [J ] . 中华心血管病杂志， 2010 ， 38 （ 8 ）： 717 - 745 ..

TUFARO V ， TORII R ， ABEN J P ， et al . Can fast wall shear stress computation predict adverse cardiac events in patients with intermediate non-flow limiting stenoses [J ] . Atherosclerosis ， 2025 ， 401 ： 119099 .

BEKLER O ， KURTUL A . Non-dipping pattern is associated with periprocedural myocardial infarction in hypertensive patients undergoing elective percutaneous coronary intervention [J ] . Medicina ， 2025 ， 61 （ 5 ）： 794 .

BODEN W E ， DE CATERINA R ， KASKI J C ， et al . Myocardial ischemic syndromes：a new nomenclature to harmonize evolving international clinical practice guidelines [J ] . Circulation ， 2024 ， 150 （ 20 ）： 1631 - 1637 .

MICHOS E ， NARLA V ， BLAHA M ， et al . The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations：perspectives，outcomes，and consequences [J ] . Vasc Health Risk Manag ， 2009 ： 1033 .

UEKI Y ， ITAGAKI T ， KUWAHARA K . Lipid-lowering therapy and coronary plaque regression [J ] . J Atheroscler Thromb ， 2024 ， 31 （ 11 ）： 1479 - 1495 .

JESWANI B M ， SHARMA S ， RATHORE S S ， et al . PCSK9 inhibitors：the evolving future [J ] . Health Sci Rep ， 2024 ， 7 （ 11 ）： e70174 .

YURTSEVEN E ， BAYSAL K ， İNCIR S ， et al . Association between HNP1-3 and atherosclerotic plaque burden in subclinical atherosclerosis and the mediating effect of PCSK9 [J ] . Clinical Translational Sci ， 2025 ， 18 （ 10 ）： e70369 .

陈心怡，赵国力，尹德录 . 冠状动脉腔内影像学评估斑块性质的研究进展 [J ] . 临床心血管病杂志， 2023 ， 39 （ 9 ）： 667 - 673 .

MASTRANGELO A ， ROBLES-VERA I ， MAÑANES D ， et al . Imidazole propionate is a driver and therapeutic target in atherosclerosis [J ] . Nature ， 2025 ， 645 （ 8079 ）： 254 - 261 .

LAGUNAS-RANGEL F A ， LIEPINSH E ， FREDRIKSSON R ， et al . Off-target effects of statins：molecular mechanisms，side effects and the emerging role of kinases [J ] . British J Pharmacology ， 2024 ， 181 （ 20 ）： 3799 - 3818 .

张云球，宋雪岩，李易莲 . 依洛尤单抗在不同血糖控制状态下糖尿病患者中的应用 [J ] . 分子诊断与治疗杂志， 2024 ， 16 （ 9 ）： 1652 - 1655，1660 .

GABA P ， O’DONOGHUE M L ， PARK J G ， et al . Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes：an analysis of FOURIER-OLE [J ] . Circulation ， 2023 ， 147 （ 16 ）： 1192 - 1203 .

NICHOLLS S J ， PURI R S ， ANDERSON T ， et al . Effect of evolocumab on progression of coronary disease in statin-treated patients：the GLAGOV randomized clinical trial [J ] . JAMA ， 2016 ， 316 （ 22 ）： 2373 .

傅源源，周建成，邹颖，等 . PCSK9抑制剂预防高胆固醇血症患者心血管疾病的药物经济学评价系统综述 [J ] . 中国药房， 2024 ， 35 （ 8 ）： 972 - 979 .

SCHETTLER V J J . Lipoprotein apheresis：current overview and future outlook in clinical practice [J ] . Transfus Apher Sci ， 2025 ， 64 （ 5 ）： 104209 .

FUJINO M ， DI GIOVANNI G ， BUTTERS BHSC J ， et al . Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes：insights from HUYGENS [J ] . Atherosclerosis ， 2025 ， 403 ： 119145 .

ZIMERMAN A ， KUNZLER A L F ， WEBER B N ， et al . Intensive lowering of LDL cholesterol levels with evolo-cumab in autoimmune or inflammatory diseases：an analysis of the FOURIER trial [J ] . Circulation ， 2025 ， 151 （ 20 ）： 1467 - 1476 .

曾粤湘 . PCSK9抑制剂联合中等剂量他汀类药物治疗对颅内动脉粥样硬化性狭窄患者的影响以及作用机制的研究 [D ] . 广州：南方医科大学， 2025 .

MEMBERS W C ， BLUMENTHAL R S ， MORRIS P B ， et al . 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia：a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines [J ] . Circulation ， 2026 ， 153 （ 17 ）： e1154 - e1276 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性比较

瑞舒伐他汀与阿托伐他汀对冠心病患者血脂、动脉粥样硬化程度和血管内皮舒张功能的疗效对比

Construction and validation of a medication deviation prediction model for hospital-to-home transition period in coronary heart disease patients with initial treatment

Clinical rapid evaluation of proprotein convertase subtilisin/kexin type 9 inhibitors for hypercholesterolemia

前列腺素E1联合阿托伐他汀对老年高血压肾病患者相关指标的

Related Author

ZHANG Like

CHEN Yu

YAO Lijun

CHEN Tan

LI Yushuang

LI Shu

ZHANG Qianying

HUANG Yan

Related Institution

Dept. of Pharmacy， the Affiliated Hospital of North China University of Science and Technology

School of Pharmacy， North China University of Science and Technology

Dept. of Pharmacy， the Second Affiliated Hospital of Hebei Northern University

School of Medicine， University of Electronic Science and Technology of China

Dept. of Pharmacy， Sichuan Academy of Medical Sciences， Sichuan Provincial People’s Hospital （Affiliated Hospital of University of Electronic Science and Technology of China）/Personalized Drug Research and Therapy Key Laboratory of Sichuan Province

⁰